Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.
Burger
D M
DM
Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands.
Hugen
P W
PW
van der Ende
M E
ME
van Wijngaarden
P
P
Aarnoutse
R E
RE
Reiss
P
P
Lange
J M
JM
D019380:Anti-HIV Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects* / Q000493:pharmacokinetics*; D008297:Male; D010865:Pilot Projects; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; D019438:Ritonavir